Training Example: Rapivab (BioCryst Pharmaceuticals) – Review the Data, Give Your Score & Compare to the Real AI Evaluation

Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims: advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags: FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns: homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations: specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…

Rapivab (BioCryst Pharmaceuticals)

(https://rapivab.com) 📸 Data Snapshot: May 24, 2026

Analyze the raw signals below. How would a machine score this business’s credibility?

Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.

🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Flu Antiviral | Rapivab (https://rapivab.com)
Title

Flu Antiviral | Rapivab

H1 It’s easy to access and order Rapivab
H2 Top Menu
H2 Top Menu
H2 Footer menu
H3 See what makes Rapivab stand out as an antiviral influenza treatment
H4 A FULL COURSE of ANTIVIRAL INFLUENZA TREATMENT IN
H4 SHORTENED TIMEto alleviation of symptoms by a median of
H4 SHORTENED TIMEto resolution of fever by a median of
H4 RAPIVAB® (peramivir injection) Important Safety Information
H5 In patients aged 6 months to 17 years, symptoms were resolved in a median of 79 hours vs. 100 hours for oseltamivir1
H5 In patients aged 6 months to 17 years, fever was resolved in a median of 40 hours vs. 35 hours for oseltamivir1,2
H5 Indication
H5 Limitations of Use
H5 Contraindications
H5 Warnings and Precautions
H5 Adverse Reactions
H5 Concurrent Use With Live Attenuated Influenza Vaccine
H5 Please see full prescribing information for RAPIVAB.
NAV_HEADER_REPEATED Dosing and Administration | Rapivab (https://rapivab.com/dosing-and-administration/)
Title

Dosing and Administration | Rapivab

H1 Dosing & Administration
H2 Top Menu
H2 Top Menu
H2 Footer menu
H3 One 15- to 30-minute intravenous (IV) infusion provides a full course of antiviral influenza treatment1
H3 Preparation of Rapivab for IV infusion
H4 Follow the steps below to prepare a diluted solution of Rapivab1:
H4 RAPIVAB® (peramivir injection) Important Safety Information
H5 Indication
H5 Limitations of Use
H5 Contraindications
H5 Warnings and Precautions
H5 Adverse Reactions
H5 Concurrent Use With Live Attenuated Influenza Vaccine
H5 Please see full prescribing information for RAPIVAB.
NAV_HEADER_REPEATED How Supplied | Rapivab (https://rapivab.com/how-supplied/)
Title

How Supplied | Rapivab

H1    How Supplied
H2 Top Menu
H2 Top Menu
H2 Footer menu
H3 Rapivab® (peramivir injection) is supplied in convenient single-use vials
H4 RAPIVAB® (peramivir injection) Important Safety Information
H5 Indication
H5 Limitations of Use
H5 Contraindications
H5 Warnings and Precautions
H5 Adverse Reactions
H5 Concurrent Use With Live Attenuated Influenza Vaccine
H5 Please see full prescribing information for RAPIVAB.
NAV_HEADER_REPEATED Coding and Billing | Rapivab (https://rapivab.com/coding-and-billing/)
Title

Coding and Billing | Rapivab

H1 Coding and Billing
H2 Top Menu
H2 Top Menu
H2 Footer menu
H3 Coding and billing information for Rapivab® (peramivir injection)
H3 Support and access for Rapivab
H4 RAPIVAB CUSTOMER SUPPORT CENTER 1-833-964-2956 and rapivab.com
H4 RAPIVAB® (peramivir injection) Important Safety Information
H5 Indication
H5 Limitations of Use
H5 Contraindications
H5 Warnings and Precautions
H5 Adverse Reactions
H5 Concurrent Use With Live Attenuated Influenza Vaccine
H5 Please see full prescribing information for RAPIVAB.
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://rapivab.com) Flu Antiviral | Rapivab
[IMG: Rapivab]
[H3] See what makes Rapivab stand out as an antiviral influenza treatment

[H4] A FULL COURSE of ANTIVIRAL INFLUENZA TREATMENT IN

[H4] SHORTENED TIMEto alleviation of symptoms by a median of

[H5] In patients aged 6 months to 17 years, symptoms were resolved in a median of 79 hours vs. 100 hours for oseltamivir1

[H4] SHORTENED TIMEto resolution of fever by a median of

[H5] In patients aged 6 months to 17 years, fever was resolved in a median of 40 hours vs. 35 hours for oseltamivir1,2

[H1] It’s easy to access and order Rapivab

To order, please call 1-833-964-2956 if you are a US-based institution or health care professional.
ORDER RAPIVAB
References: 1. Rapivab [package insert]. Durham, NC: BioCryst Pharmaceuticals, Inc; 2021. 2. Kohno S, Kida H, Mizuguchi M, Shimada J; S-021812 Clinical Study Group. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother. 2010;54(11):4568-4574. 3. BioCryst Pharmaceuticals, Inc. Summary of clinical efficacy. Data on file. 4. Managed Markets Insights & Technology, LLC website. https://formularylookup.com/. Accessed March 16, 2021.
1191 chars
SUB-PAGE (https://rapivab.com/dosing-and-administration/) Dosing and Administration | Rapivab
[H1] Dosing &
Administration

[H3] One 15- to 30-minute intravenous (IV) infusion provides a full course of antiviral influenza treatment1
Use these dosing guidelines to determine the dosage of Rapivab® (peramivir injection) for your patients 6 months of age and older.

The administration of Rapivab in patients with renal impairment is at the discretion of the treating physician.

[H3] Preparation of Rapivab for IV infusion
Use aseptic technique during the preparation of Rapivab to prevent inadvertent microbial contamination. There is no preservative or bacteriostatic agent present in the solution.1
[H4] Follow the steps below to prepare a diluted solution of Rapivab1:

1. Do not use if seal over bottle opening is broken or missing.
2. Visually inspect Rapivab for particulate matter and discoloration prior to administration.
3. Dilute an appropriate dose of RAPIVAB 10 mg/mL solution [see Dosage and Administration (2.1, 2.2)] in 0.9% or 0.45% sodium chloride, 5% dextrose, or lactated Ringer’s. The maximum infusion volume is provided in Table 3. The final concentration of diluted RAPIVAB for administration should be between 1 mg/mL and 6 mg/mL.
4. Administer the diluted solution via intravenous infusion for 15 to 30 minutes.
5. Discard any unused diluted solution of Rapivab after 24 hours.
Once a diluted solution of Rapivab has been prepared, administer immediately or store under refrigerated conditions (2° to 8°C or 36° to 46°F) for up to 24 hours. If refrigerated, allow the diluted solution of Rapivab to reach room temperature, then administer immediately.
Do not use if seal over bottle opening is broken or missing.
Reference: 1. Rapivab [package insert]. Durham, NC: BioCryst Pharmaceuticals, Inc; 2021.
1744 chars
SUB-PAGE · THIN (https://rapivab.com/how-supplied/) How Supplied | Rapivab
[H1]    How
Supplied

[H3] Rapivab® (peramivir injection) is supplied in convenient single-use vials

Each single-use vial of Rapivab contains 200 mg per 20 mL (10 mg/mL) of peramivir in a clear glass vial (NDC #72769-181-01).1
Rapivab is supplied in cartons containing 3 single-use vials (NDC #72769-181-03).1

Reference: 1. Rapivab [package insert]. Durham, NC: BioCryst Pharmaceuticals, Inc; 2021.
412 chars
SUB-PAGE (https://rapivab.com/coding-and-billing/) Coding and Billing | Rapivab
[H1] Coding
and Billing

[H3] Coding and billing information for Rapivab® (peramivir injection)
Use this information to facilitate coding and billing processes. Some payers will require the National Drug Code (NDC) code for Rapivab.1

[H3] Support and access for Rapivab

[H4] RAPIVAB CUSTOMER SUPPORT CENTER
1-833-964-2956 and rapivab.com

Current Procedural Terminology (CPT) Codes for Rapivab

The following CPT codes are for treatments administered via injection to individuals.

CPT Code 2
Description

96365
Intravenous (IV) infusion for therapy, prophylaxis, or diagnosis; initial, up to first hour

96366
IV med therapy−each additional hour

96374
IV med injection−first med

96375
IV med injection−second med subsequent injection

96376
IV med injection−first med subsequent injection

96360
IV hydration−first hour

96361
IV hydration−each additional hour

HCPCS Code 3
Description

J2547
Injection, peramivir, 1 mg

Report the administration of Rapivab in addition to the treatment product code
Assign the appropriate administration code based on the documentation in the medical record
Medicare requires the use of an HCPCS code for the administration of Rapivab. Some payers may also require that an HCPCS code be used to report Rapivab

Prior authorizations or appeals may not be completed or filed on the HCP's behalf.

Revenue codes for Rapivab

These codes are used to attribute hospital charges to specific cost centers. They may vary by service provided and patient status.

Revenue Code 4
Description

0636
Drugs requiring detailed coding required by Medicare to obtain pass-through payment for drugs in the outpatient department

0250
Pharmacy, general

0260
Intravenous therapy, general

0450
Emergency room

0510
Clinic

0520
IV hydration–first hour

ICD-10-CM codesa for Rapivab

Refer to these tables when you need the ICD-10-CM codes for Rapivab.

ICD-10 Code 5
Description

J10.00
Influenza due to other identified influenza virus with unspecified type of pneumonia

J10.01
Influenza due to other identified influenza virus with the same other identified influenza virus pneumonia

J10.08
Influenza due to other identified influenza virus with other specified pneumonia

J11.00
Influenza due to unidentified influenza virus with unspecified type of pneumonia

J11.08
Influenza due to unidentified influenza virus with specified pneumonia

J12.9
Viral pneumonia, unspecified

J10.1
Influenza due to other identified influenza virus with other respiratory manifestations

J11.1
Influenza due to unidentified influenza virus with other respiratory manifestations

J10.2
Influenza due to other identified influenza virus with gastrointestinal manifestations

J10.81
Influenza due to other identified influenza virus with encephalopathy

J10.82
Influenza due to other identified influenza virus with myocarditis

J10.83
Influenza due to other identified influenza virus with otitis

J10.89
Influenza due to other identified influenza virus with other manifestations

J11.2
Influenza due to unidentified influenza virus with gastrointestinal manifestations

J11.81
Influenza due to unidentified influenza virus with encephalopathy

J11.82
Influenza due to unidentified influenza virus with myocarditis

J11.83
Influenza due to unidentified influenza virus with otitis media

J11.89
Influenza due to unidentified influenza virus with other manifestations

J09.X1
Influenza due to identified novel influenza A virus with pneumonia

J09.X2
Influenza due to identified novel influenza A virus with other respiratory manifestations

J09.X3
Influenza due to identified novel influenza A virus with gastrointestinal manifestations

J09.X9
Influenza due to identified novel influenza A virus with other manifestations

aThis may not be an all-inclusive list; see payor-specific coverage policies for covered indication.

References: 1. Rapivab [package insert]. Durham, NC: BioCryst Pharmaceuticals, Inc; 2021. 2. Current Procedural Coding Expert; 2021 Chicago IL: Optum360; 2021. 3. Parman C. Hospital regulatory update. Association of Community Cancer Centers website. https://www.accc-cancer.org/oncology_issues/articles/JF16/JF16-Oncology-Coding-Reimbursement-Update.pdf. Accessed March 16, 2021. 4. CMS Manual System: Pub. 100-04 Medicare claims processing. Centers for Medicare & Medicaid Services website. https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/r167cp.pdf. Published April 30, 2004. Accessed March 16, 2021. 5. Nelson M. ICD-10 cometh. https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=5&cad=rja&uact=8&ved=0ahUKEwih4NKzjLfLAhXLTCYKHc2LAAUQFgg5MAQ&url=https%3A%2F%2Fwww.chestnet.org%2F~%2Fmedia%2Fchesnetorg%2FPublications%2FDocuments%2FCHEST%2520Physician%2FICD10InfluenzaCodes.ashx&usg=AFQjCNH5tCT-_gZ8SmRF_CZi0vB-OvUyFQ&sig2=JQocAaPEHmQ0wQsagrgHLQ&bvm=bv.116573086,d.cWw. Published April 2015. Accessed March 16, 2021.
5180 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
0Review mentions (all pages)
0External proof links (all pages)
PageReviewsProof links
/ (home) 0 0
/dosing-and-administration/ 0 0
/how-supplied/ 0 0
/coding-and-billing/ 0 0
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage — no schema detected (entity gap)
/dosing-and-administration/ — no schema detected (entity gap)
/how-supplied/ — no schema detected (entity gap)
/coding-and-billing/ — no schema detected (entity gap)

Your Diagnosis

Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.

Information Density 0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence 0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof 0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint 0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority 0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score 0 / 100
💡 Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)

These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.

Information Density

Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.

Semantic Alignment

Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.

Trust & Proof

Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.

Commodity Fingerprint

Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.

Identity & Authority

Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.

Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.

B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS

Based on 784 businesses audited.

BS Detector

Medical Devices, Pharma & Biotech BS: Rapivab (BioCryst Pharmaceuticals) (rapivab.com)

https://rapivab.com 📍 Industry: Medical Devices, Pharma & Biotech
7 BS / 100

This is an exceptionally low-BS clinical resource that prioritizes technical utility for healthcare providers over marketing fluff. Its data-heavy approach to billing, dosing, and efficacy provides immediate substance that justifies its claims. The only significant detractors are the lack of modern structured data and the aging reference citations.

Info Density Power-words vs. Substance ratio.
1
3% BS
Semantic Coherence Homepage promise vs. Sub-page reality.
0
0% BS
Trust & Proof Verifiable evidence vs. Trust Theatre.
0
0% BS
Commodity Fingerprint Detection of industry clichés/templates.
1
7% BS
Identity & Authority Expert verifiability & Schema depth.
5
33% BS

Implement MedicalEntity and Drug schema.org structured data to explicitly define the drug’s indication and dosage for search engines. Update the ‘Coding and Billing’ section to explicitly state it reflects current 2026 CMS guidelines, as the current 2021 references are temporally stale. Include a ‘Last Updated’ timestamp on clinical data to reassure HCPs of the medication’s current standing in the therapeutic area. Add direct, high-visibility links to the latest peer-reviewed real-world evidence (RWE) published between 2021 and 2026.

The website perfectly aligns with the Pharmaceutical and Biotech industry, specifically focusing on a prescribed antiviral medication. The content is heavily regulated, technical, and targeted toward healthcare professionals, evidenced by the inclusion of Important Safety Information and clinical dosing guidelines.

“The score of 7 is driven primarily by the site's technical staleness and lack of structured identity data (Pillar 5). It earned nearly perfect scores in Information Density and Trust and Proof due to its exhaustive use of NDCs, CPT codes, and clinical trial citations. The site represents the antithesis of 'Business BS,' serving as a functional tool rather than a promotional brochure.”

Verified Analysis Date: May 24, 2026 © 1EuroSEO Independent Evaluator — Non-Sponsored Result
Brand AI Reputation